EP1226150A4 - TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA - Google Patents

TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA

Info

Publication number
EP1226150A4
EP1226150A4 EP00973739A EP00973739A EP1226150A4 EP 1226150 A4 EP1226150 A4 EP 1226150A4 EP 00973739 A EP00973739 A EP 00973739A EP 00973739 A EP00973739 A EP 00973739A EP 1226150 A4 EP1226150 A4 EP 1226150A4
Authority
EP
European Patent Office
Prior art keywords
overexprised
tadg
carcinoma
serine protease
extracellular serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00973739A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1226150A1 (en
Inventor
Timothy J O'brien
Hirotoshi Tanimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas at Fayetteville
University of Arkansas at Little Rock
Original Assignee
University of Arkansas at Fayetteville
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/421,213 external-priority patent/US7022821B1/en
Application filed by University of Arkansas at Fayetteville, University of Arkansas at Little Rock filed Critical University of Arkansas at Fayetteville
Priority to EP07118615A priority Critical patent/EP1887082A3/en
Publication of EP1226150A1 publication Critical patent/EP1226150A1/en
Publication of EP1226150A4 publication Critical patent/EP1226150A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP00973739A 1999-10-20 2000-10-20 TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA Withdrawn EP1226150A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07118615A EP1887082A3 (en) 1999-10-20 2000-10-20 TADG-15: An extracellular serine protease overexpressed in carcinomas

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US421213 1999-10-20
US09/421,213 US7022821B1 (en) 1998-02-20 1999-10-20 Antibody kit for the detection of TADG-15 protein
PCT/US2000/029095 WO2001029056A1 (en) 1999-10-20 2000-10-20 Tadg-15: an extracellular serine protease overexpressed in carcinomas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07118615A Division EP1887082A3 (en) 1999-10-20 2000-10-20 TADG-15: An extracellular serine protease overexpressed in carcinomas

Publications (2)

Publication Number Publication Date
EP1226150A1 EP1226150A1 (en) 2002-07-31
EP1226150A4 true EP1226150A4 (en) 2005-05-25

Family

ID=23669632

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00973739A Withdrawn EP1226150A4 (en) 1999-10-20 2000-10-20 TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA
EP07118615A Withdrawn EP1887082A3 (en) 1999-10-20 2000-10-20 TADG-15: An extracellular serine protease overexpressed in carcinomas

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07118615A Withdrawn EP1887082A3 (en) 1999-10-20 2000-10-20 TADG-15: An extracellular serine protease overexpressed in carcinomas

Country Status (6)

Country Link
EP (2) EP1226150A4 (enExample)
JP (1) JP2003512036A (enExample)
AU (1) AU774106B2 (enExample)
CA (1) CA2388450C (enExample)
MX (1) MXPA02004046A (enExample)
WO (1) WO2001029056A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795211B2 (en) * 2000-02-22 2010-09-14 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
DK2185933T3 (en) * 2007-08-07 2015-10-26 Oxford Biotherapeutics Ltd MATRIPTASE PROTEIN AND APPLICATIONS THEREOF
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
EP3211421A1 (en) 2010-09-09 2017-08-30 Traxxsson, LLC Combination methods of diagnosing cancer in a patient
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
KR20160079818A (ko) 2013-11-25 2016-07-06 옥스포드 바이오테라퓨틱스 리미티드 암 치료용 항-매트립타제 항체
US9272027B1 (en) 2014-09-08 2016-03-01 The United States Of America As Represented By The Secretary Of The Air Force Francisella tularensis live vaccine strains and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO1999042120A1 (en) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09149790A (ja) * 1995-09-29 1997-06-10 Suntory Ltd 新規セリンプロテアーゼ
AU2501200A (en) * 1999-01-11 2000-08-01 Incyte Pharmaceuticals, Inc. Human peptidases
CA2362670A1 (en) * 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
WO1999036550A2 (en) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Human protease molecules
WO1999042120A1 (en) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0129056A1 *

Also Published As

Publication number Publication date
AU1221501A (en) 2001-04-30
EP1887082A2 (en) 2008-02-13
JP2003512036A (ja) 2003-04-02
CA2388450A1 (en) 2001-04-26
EP1887082A3 (en) 2008-06-11
MXPA02004046A (es) 2002-10-11
AU774106B2 (en) 2004-06-17
EP1226150A1 (en) 2002-07-31
CA2388450C (en) 2013-02-12
WO2001029056A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
DE50012572D1 (de) Detergensgemische
DE60125859D1 (de) Poliervorrichtung
DE60129488D1 (de) Anzeigegerät
ID30007A (id) Gaun sekali pakai
DK0979240T3 (da) Serinproteaseinhibitor
EP1207511A4 (en) DISPLAY
ID29885A (id) Penghambat serina protease
DE60108470D1 (de) Transparentes Seifenstück
DE50105593D1 (de) Schleifvorrichtung
DE60038157D1 (de) Baumaschine
NO20032390D0 (no) Serotonerge midler
NO20030095L (no) Slipeapparat
DE50105754D1 (de) Schleifvorrichtung
EP1226150A4 (en) TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA
DE60122236D1 (de) Poliervorrichtung
FI20000508L (fi) Murskain
DE60144430D1 (de) Subtilase varianten
DE50104735D1 (de) Schleifvorrichtung
DE50011864D1 (de) Tensidmischungen
ATA1322000A (de) Beregnungsmaschine
ITBO20000623A0 (it) Macchina levigatrice
DE50115725D1 (de) Schleifmaschine
FI20002338L (fi) Menetelmä työkoneessa
IT1315617B1 (it) Macchina falciatrice
ATE382429T1 (de) Brecherkopf

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050406

17Q First examination report despatched

Effective date: 20050928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071030